That differential, for five games, is larger than that of 18 major league teams after over 90 games, in either direction.

Vornado Realty Trust, Brent Oil Futures, American Assets Trust Inc, Brandywine Realty Trust. Read 's Market Analysis on Investing.com ...

ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025.

ALX Nigeria has unveiled Creative Tech Lite, a new initiative designed to equip the continent’s creators with in-demand digital skills. Touted as a game-changer for Africa’s creative economy ...

ALX Oncology Holdings Inc., a pharmaceutical company based in South San Francisco, California, has been notified of its non-compliance with a Nasdaq listing requirement. On April 23, 2025, the ...

ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025.

ALX held total debt of $988 million as of the end of its fourth quarter. The $300 million of debt held on 731 Lexington retail is also held at a ZIRP era rate of interest at 1.76%.

--ALX Oncology Holdings Inc.,, a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced receipt of U.S ...

ALX, Africa’s leading tech career accelerator, is celebrating a major win for young African talent as 21 exceptional learners from the ALX Pathway program secure prestigious scholarships from ...

The film chronicles the political and social landscape of early 20th century America, focusing on the transition from the innocence of the Roosevelt era to the complexities of the Wilson ...

ALX said its loss for the three months ended Dec. 31 was 55 cents a share, compared with a loss of 93 cents in the year-earlier period, due to lower research and development expenses.

During the R&D Day event, ALX Oncology leadership will discuss the mechanistic rationale and clinical data that support further development of evorpacept with anti-cancer antibodies. In addition ...